The United Kingdom's dysphagia management business revenue is expected to increase from USD 232.4 million in 2023 to USD 293.3 million by 2033. Over the forecast period, demand for dysphagia management products across the United Kingdom is predicted to rise at a CAGR of 2.4%. Total revenue from the dysphagia management business in the United Kingdom totaled USD 228.2 million at the end of 2022.
The rising prevalence of neurological disorders, structural abnormalities, or other medical conditions is expected to push the cases of dysphagia worldwide. The growing need for treating this condition is expected to drive the demand for dysphagia management solutions.
Key companies are focusing on developing new drugs and medical devices for the management of swallowing disorders in the United Kingdom. This is expected to foster growth in the United Kingdom’s dysphagia management business.
Other Factors Driving Dysphagia Management Demand in the United Kingdom-
| Attributes | Key Insights |
|---|---|
| Dysphagia Management Business Size in the United Kingdom (2022) | USD 228.2 million |
| Estimated United Kingdom Dysphagia Management Business Revenue (2023) | USD 232.4 million |
| Projected United Kingdom Dysphagia Management Business Revenue (2033) | USD 293.3 million |
| Value-based CAGR (2023 to 2033) | 2.4% |
The United Kingdom dysphagia management business recorded a CAGR of 1.2% from 2018 to 2022. Total revenue in the country reached USD 228.2 million at the end of 2022. Over the assessment period, dysphagia management demand in the United Kingdom is predicted to increase at a 2.4% CAGR.
| Historical CAGR (2018 to 2022) | 1.2% |
|---|---|
| Forecast CAGR (2023 to 2033) | 2.4% |
Several factors are expected to spur growth in the United Kingdom's dysphagia management business. These include the rising prevalence of dysphagia and other swallowing disorders, growing health awareness, and increasing spending on swallowing disorder treatment in the United Kingdom.
Dysphagia is especially prevalent among the geriatric population. For instance, studies suggest that dysphagia is thought to affect around 4 million people in the United Kingdom. This will continue to drive demand for dysphagia management solutions.
Certain chronic health conditions, such as gastroesophageal reflux disease (GERD), muscular dystrophy, and scleroderma, can result in dysphagia. Hence, the increasing prevalence of these conditions is expected to create lucrative opportunities for dysphagia management companies.
In the United Kingdom, the National Health Service (NHS) and the Department of Health and Social Care are playing a key role in tackling the burden of swallowing disorders, including dysphagia. This will positively impact overall dysphagia management product sales.
For instance, the Speech and Language Therapy service at Sheffield Teaching Hospital’s NHS Foundation Trust launched a novel bite-sized online learning resource to improve the understanding of dysphagia. These initiatives are likely to boost dysphagia management solution sales.
Dysphagia can lead to feelings of frustration, embarrassment, and isolation. Difficulty in eating and drinking can result in a reduced quality of life, impacting an individual's social interactions and overall happiness. Hence, the importance of dysphagia management is proliferating.
Dysphagia is commonly seen in patients with neurological disorders and stroke. The main symptoms of dysphagia in neurological disorders are delayed oral transit and difficulties in bolus formation, among others. To treat this condition, patients are expected to opt for dysphagia management solutions, including PPIs, feeding devices, and nutritional supplements.
To avoid difficulties in swallowing solid foods, consumers are showing interest in dysphagia supplement products such as powder thickeners and gel thickeners. The increasing adoption of these supplements will boost the total dysphagia management business revenue.
Greater awareness about dysphagia means that healthcare professionals are more likely to identify and diagnose swallowing disorders at an early stage. This can lead to quicker interventions and better outcomes for individuals with dysphagia.
The recognition of dysphagia as a significant health concern can drive research and innovation in the field. This can lead to the development of new diagnostic tools, therapies, and products designed to improve the quality of life for individuals with dysphagia.
The increasing awareness of dysphagia in the United Kingdom and emerging countries is a positive development that can lead to better healthcare outcomes and increased access to dysphagia management services. It will also create new opportunities for innovation and collaboration in the field of dysphagia management.
The usage of equipment in high-risk anatomical regions, including the anterior neck, requires specific clearance from the Food & Drug Administration (FDA). The general clearance for neuromuscular stimulation/reeducation is not sufficient. This is acting as an impediment for companies.
Contrary to other body parts, the FDA has always issued a warning label for the use of neuromuscular electrical stimulation (NMES) on the anterior neck. This is because there is a chance of severe harm or death while utilizing general clearance NMES devices and supplies on the neck. This factor is limiting the growth of the target business to a certain extent.
Long-term use of dysphagia drugs such as proton pump inhibitors is associated with certain threats, such as the increased risk of hip bone fracture. This is due to the decreased absorption of calcium and iron and the risk of opportunistic infections with S. pneumonia and C. defficile owing to diminished natural gut flora.
The use of nasogastric tubes or PEG tubes can cause irritation to the throat, which leads to severe discomfort. Long-term administration of such tubes can cause abdominal cramping, abdominal swelling, diarrhea, nausea, vomiting, and regurgitation of food and medicines.
Dysphagia drugs, such as proton pump inhibitors (PPIs) and H2 blockers, are expected to be commonly used to treat GERD, a condition that can cause dysphagia. While these drugs are generally safe and effective, they can cause side effects such as headache, diarrhea, and abdominal pain.
In a handful of cases, long-term use of PPIs has been linked to an increased risk of certain health conditions, such as bone fractures, kidney disease, and other infections. Hence, the side effects of PPIs and feeding tubes can limit their usage, thereby hampering the expansion of the target business.
Growth Outlook by Key States
| States | Value CAGR |
|---|---|
| Greater London | 1.9% |
| West Midlands | 2.8% |
| Greater Manchester | 3.6% |
| West Yorkshire | 5.7% |
| Glasgow | 2.6% |
As per the latest report, Greater London is projected to remain a lucrative pocket for dysphagia management companies across England. Over the forecast period, the demand for dysphagia management solutions in Greater London is projected to rise at a 1.9% CAGR.
By 2033, Greater London’s dysphagia management business revenue is anticipated to reach USD 46.8 million. It will likely hold a share of 21.1% in England by the end of 2033. This is attributable to the rising incidence of dysphagia.
Dysphagia often results from underlying medical conditions such as stroke, Parkinson's disease, and dementia. Greater London's diverse and growing population can experience a higher prevalence of these conditions, driving the demand for dysphagia management.
Awareness among healthcare professionals and the public regarding the diagnosis and management of dysphagia is also growing rapidly in Greater London. This can lead to early diagnosis and intervention, increasing the need for related services.
West Midlands is projected to experience a CAGR of 2.8% during the forecast period. Total dysphagia management sales in the West Midlands are set to reach USD 23.0 million by 2033. The presence of rehabilitation centers and long-term care facilities in the region can drive the demand for dysphagia management products and services, as these institutions often cater to patients with swallowing difficulties.
The presence of well-established healthcare infrastructure, including hospitals, clinics, and skilled healthcare professionals specializing in dysphagia management, can encourage patients to seek treatment across the region. This will boost overall revenue in the West Midlands through 2033.
The section below shows the drugs segment witnessing a higher CAGR of 5.2% during the assessment period. Based on indication, the oropharyngeal dysphagia category is expected to hold a prominent value share by 2033, exhibiting a CAGR of 1.5%. By distribution channel, the hospital pharmacies segment will retain its dominance in the United Kingdom, thriving at a 1.2% CAGR through 2033.
Growth Outlook by Key Product
| Product | Value CAGR |
|---|---|
| Drugs (Proton Pump Inhibitors) | 5.2% |
| Feeding Tubes | 1.6% |
| Nutritional Solutions | 2.2% |
| Devices | 4.1% |
Based on product, the drugs (proton pump inhibitors) segment is expected to thrive at a 5.2% CAGR during the forecast period. As a result, dysphagia management companies looking to boost their revenue will likely shift their focus on offering novel and effective proton pump inhibitors.
Proton pump inhibitors (PPIs) are primarily prescribed to reduce stomach acid production. By managing conditions such as GERD and acid reflux, which are common causes of dysphagia, PPIs help alleviate the symptoms and underlying causes of swallowing difficulties. This, in turn, leads to better dysphagia management.
PPIs can also help reduce the discomfort associated with acid-related conditions, making it easier for individuals with dysphagia to eat and swallow. This improved comfort can lead to better patient compliance with dysphagia management plans.
Growth Outlook by Indication
| Indication | Value CAGR |
|---|---|
| Oropharyngeal Dysphagia | 1.5% |
| Esophageal Dysphagia | 5.2% |
As per the latest dysphagia management industry analysis, the oropharyngeal dysphagia segment is set to create lucrative revenue generation for dysphagia management companies. This is attributed to the rising prevalence of oropharyngeal dysphagia in the United Kingdom.
The oropharyngeal dysphagia segment is anticipated to expand at a 1.5% CAGR during the forecast period. It is expected to total USD 218.2 million by 2033, accounting for a value share of 74.4% in the United Kingdom.
Oropharyngeal dysphagia patients frequently require speech therapy and rehabilitation to improve their swallowing function. This drives the demand for speech therapists, drugs, medical devices, and rehabilitation facilities, which are key components of the dysphagia management business.
Oropharyngeal dysphagia treatment plans are often tailored to the individual's specific needs and the underlying causes of the condition. This personalization of care can result in a variety of management options and interventions, including dietary modifications and exercises, all of which contribute to revenue growth.
Growth Outlook by Key End-user
| Application | Value CAGR |
|---|---|
| Hospital Pharmacies | 1.2% |
| Retail Pharmacies | 1.8% |
| Drug Stores | 2.9% |
| Specialty Clinics | 5.1% |
Based on end-users, the hospital pharmacies segment is projected to expand at a 1.2% CAGR during the assessment period. As per the latest analysis of dysphagia management in the United Kingdom, the target segment will likely hold a share of about 36.2% by 2033.
Hospital pharmacies are responsible for dispensing medications to patients within the hospital. For dysphagia patients, this can include specialized oral medications or alternative routes of administration, such as enteral feeding through feeding tubes. The availability and proper management of these medications are essential for effective dysphagia treatment.
Strategic partnerships are a priority for leading dysphagia management companies in the United Kingdom as they work to create new product lines and expand their global consumer base. Key players are also investing heavily in research and development to develop cutting-edge dysphagia management tools in the United Kingdom.
Recent Developments in the United Kingdom Dysphagia Management Business
| Attribute | Details |
|---|---|
| Estimated Value (2023) | USD 232.4 million |
| Expected Value (2033) | USD 293.3 million |
| Anticipated Growth Rate (2023 to 2033) | 2.4% CAGR |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Industry Analysis | USD million for Value |
| Key Regions Covered | England; Wales; Scotland; Northern Ireland |
| Key States Covered | Greater London, West Midlands, Greater Manchester, West Yorkshire, Rest of England, Cardiff, Swansea, Rhondda Cynon Taf, Carmarthenshire, Rest of Wales, Glasgow, Edinburgh, Aberdeen, Lanarkshire, Rest of Scotland, Antrim, Armagh, Down, Fermanagh, Rest of Northern Ireland |
| Key Segments Covered | Product, Indication, Distribution Channel, and Region |
| Key Companies Profiled | Abbott; Nestlé Health Science; Danone S.A; Hormel Foods Corporation; Fresenius Kabi AG; Cipla Ltd; Eisai Co Ltd; Becton, Dickinson and Company (BD); Cook Medical Inc.; AstraZeneca Plc.; VitalStim UK; Nutricia Limited; Simply Food Solutions Limited; Ampcare, LLC; E2 Scientific Corp; TheraSIP LLC; Phagenesis; ProvaMed®; Kent Precision Foods Group |
| Report Coverage | Future Forecast, Competition Intelligence, Key Dynamics and Challenges, Strategic Growth Initiatives |
Table 01: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 02: Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 03: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 04: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 05: Value (US$ Million) Analysis and Forecast 2018 to 2033, by Region
Table 06: England Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 07: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 08: England Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 09: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 10: England Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 11: Wales Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 12: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 13: Wales Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 14: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 15: Wales Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 16: Scotland Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 17: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 18: Scotland Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 19: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 20: Scotland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Table 21: Northern Ireland Value (US$ Million) Analysis 2018-2022 and Forecast 2023 to 2033, by Country
Table 22: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Product
Table 23: Northern Ireland Volume (Units) Analysis and Forecast 2018 to 2033, by Product
Table 24: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Indication
Table 25: Northern Ireland Value (US$ Million) Analysis and Forecast 2018 to 2033, by Distribution Channel
Figure 01: Volume (Units), 2018 to 2022
Figure 02: Volume (Units) & Y-o-Y Growth (%) Analysis, 2023 to 2033
Figure 03: Dysphagia Management, Pricing Analysis per unit (US$), in 2023
Figure 04: Dysphagia Management, Pricing Forecast per unit (US$), in 2033
Figure 05: Value (US$ Million) Analysis, 2018 to 2022
Figure 06: Business Forecast & Y-o-Y Growth, 2023 to 2033
Figure 07: Absolute $ Opportunity (US$ Million) Analysis, 2023 to 2033
Figure 08: Value Share (%) Analysis 2023 and 2033, by Product
Figure 09: Y-o-Y Growth (%) Analysis 2023 to 2033, by Product
Figure 10: Business Attractiveness Analysis 2023 to 2033, by Product
Figure 11: Value Share (%) Analysis 2023 and 2033, by Indication
Figure 12: Y-o-Y Growth (%) Analysis 2023 to 2033, by Indication
Figure 13: Business Attractiveness Analysis 2023 to 2033, by Indication
Figure 14: Value Share (%) Analysis 2023 and 2033, by Distribution Channel
Figure 15: Y-o-Y Growth (%) Analysis 2023 to 2033, by Distribution Channel
Figure 16: Business Attractiveness Analysis 2023 to 2033, by Distribution Channel
Figure 17: Value Share (%) Analysis 2023 and 2033, by Region
Figure 18: Y-o-Y Growth (%) Analysis 2023 to 2033, by Region
Figure 19: Business Attractiveness Analysis 2023 to 2033, by Region
Figure 20: England Value (US$ Million) Analysis, 2018 to 2022
Figure 21: England Value (US$ Million) Forecast, 2023 to 2033
Figure 22: England Value Share, by Product (2023 E)
Figure 23: England Value Share, by Indication (2023 E)
Figure 24: England Value Share, by Distribution Channel (2023 E)
Figure 25: England Value Share, by Country (2023 E)
Figure 26: England Business Attractiveness Analysis by Product, 2023 to 2033
Figure 27: England Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 28: England Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 29: England Business Attractiveness Analysis by Country, 2023 to 2033
Figure 30: Greater London Value Proportion Analysis, 2022
Figure 31: Global Vs. Greater London Growth Comparison
Figure 32: Greater London Business Share Analysis (%) by Product, 2022 & 2033
Figure 33: Greater London Business Share Analysis (%) by Indication, 2022 & 2033
Figure 34: Greater London Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 35: West Midlands Value Proportion Analysis, 2022
Figure 36: Global Vs. West Midlands. Growth Comparison
Figure 37: West Midlands Business Share Analysis (%) by Product, 2022 & 2033
Figure 38: West Midlands Business Share Analysis (%) by Indication, 2022 & 2033
Figure 39: West Midlands Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 40: Global Vs. Greater Manchester. Growth Comparison
Figure 41: Greater Manchester Business Share Analysis (%) by Product, 2022 & 2033
Figure 42: Greater Manchester Business Share Analysis (%) by Indication, 2022 & 2033
Figure 43: Greater Manchester Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 44: Global Vs. Yorkshire. Growth Comparison
Figure 45: Yorkshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 46: Yorkshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 47: Yorkshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 48: Global Vs. Rest of England. Growth Comparison
Figure 49: Rest of England Business Share Analysis (%) by Product, 2022 & 2033
Figure 50: Rest of England Business Share Analysis (%) by Indication, 2022 & 2033
Figure 51: Rest of England Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 52: Wales Value (US$ Million) Analysis, 2018 to 2022
Figure 53: Wales Value (US$ Million) Forecast, 2023 to 2033
Figure 54: Wales Value Share, by Product (2023 E)
Figure 55: Wales Value Share, by Indication (2023 E)
Figure 56: Wales Value Share, by Distribution Channel (2023 E)
Figure 57: Wales Value Share, by Country (2023 E)
Figure 58: Wales Business Attractiveness Analysis by Product, 2023 to 2033
Figure 59: Wales Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 60: Wales Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 61: Wales Business Attractiveness Analysis by Country, 2023 to 2033
Figure 62: Cardiff Value Proportion Analysis, 2022
Figure 63: Global Vs Cardiff Growth Comparison
Figure 64: Cardiff Business Share Analysis (%) by Product, 2022 & 2033
Figure 65: Cardiff Business Share Analysis (%) by Indication, 2022 & 2033
Figure 66: Cardiff Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 67: Swansea Value Proportion Analysis, 2022
Figure 68: Global Vs. Swansea. Growth Comparison
Figure 69: Swansea Business Share Analysis (%) by Product, 2022 & 2033
Figure 70: Swansea Business Share Analysis (%) by Indication, 2022 & 2033
Figure 71: Swansea Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 72: Rhondda Cynon Taf Value Proportion Analysis, 2022
Figure 73: Global Vs Rhondda Cynon Taf Growth Comparison
Figure 74: Rhondda Cynon Taf Business Share Analysis (%) by Product, 2022 & 2033
Figure 75: Rhondda Cynon Taf Business Share Analysis (%) by Indication, 2022 & 2033
Figure 76: Rhondda Cynon Taf Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 77: Carmarthenshire Value Proportion Analysis, 2022
Figure 78: Global Vs Carmarthenshire Growth Comparison
Figure 79: Carmarthenshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 80: Carmarthenshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 81: Carmarthenshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 82: Rest of Wales Value Proportion Analysis, 2022
Figure 83: Global Vs Rest of Wales Growth Comparison
Figure 84: Rest of Wales Business Share Analysis (%) by Product, 2022 & 2033
Figure 85: Rest of Wales Business Share Analysis (%) by Indication, 2022 & 2033
Figure 86: Rest of Wales Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 87: Scotland Value (US$ Million) Analysis, 2018 to 2022
Figure 88: Scotland Value (US$ Million) Forecast, 2023 to 2033
Figure 89: Scotland Value Share, by Product (2023 E)
Figure 99: Scotland Value Share, by Indication (2023 E)
Figure 100: Scotland Value Share, by Distribution Channel (2023 E)
Figure 101: Scotland Value Share, by Country (2023 E)
Figure 102: Scotland Business Attractiveness Analysis by Product, 2023 to 2033
Figure 103: Scotland Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 104: Scotland Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 105: Scotland Business Attractiveness Analysis by Country, 2023 to 2033
Figure 106: Glasgow Value Proportion Analysis, 2022
Figure 107: Global Vs. Glasgow Growth Comparison
Figure 108: Glasgow Business Share Analysis (%) by Product, 2022 & 2033
Figure 109: Glasgow Business Share Analysis (%) by Indication, 2022 & 2033
Figure 110: Glasgow Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 111: Edinburgh Value Proportion Analysis, 2022
Figure 112: Global Vs. Edinburgh Growth Comparison
Figure 113: Edinburgh Business Share Analysis (%) by Product, 2022 & 2033
Figure 114: Edinburgh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 115: Edinburgh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 116: Aberdeen Value Proportion Analysis, 2022
Figure 117: Global Vs. Aberdeen Growth Comparison
Figure 118: Aberdeen Business Share Analysis (%) by Product, 2022 & 2033
Figure 119: Aberdeen Business Share Analysis (%) by Indication, 2022 & 2033
Figure 120: Aberdeen Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 121: Lanarkshire Value Proportion Analysis, 2022
Figure 122: Global Vs Lanarkshire Growth Comparison
Figure 123: Lanarkshire Business Share Analysis (%) by Product, 2022 & 2033
Figure 124: Lanarkshire Business Share Analysis (%) by Indication, 2022 & 2033
Figure 125: Lanarkshire Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 126: Rest of Scotland Value Proportion Analysis, 2022
Figure 127: Global Vs Rest of Scotland Growth Comparison
Figure 128: Rest of Scotland Business Share Analysis (%) by Product, 2022 & 2033
Figure 129: Rest of Scotland Business Share Analysis (%) by Indication, 2022 & 2033
Figure 130: Rest of Scotland Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 131: Northern Ireland Value (US$ Million) Analysis, 2018 to 2022
Figure 132: Northern Ireland Value (US$ Million) Forecast, 2023 to 2033
Figure 133: Northern Ireland Value Share, by Product (2023 E)
Figure 134: Northern Ireland Value Share, by Indication (2023 E)
Figure 135: Northern Ireland Value Share, by Distribution Channel (2023 E)
Figure 136: Northern Ireland Value Share, by Country (2023 E)
Figure 137: Northern Ireland Business Attractiveness Analysis by Product, 2023 to 2033
Figure 138: Northern Ireland Business Attractiveness Analysis by Indication, 2023 to 2033
Figure 139: Northern Ireland Business Attractiveness Analysis by Distribution Channel, 2023 to 2033
Figure 140: Northern Ireland Business Attractiveness Analysis by Country, 2023 to 2033
Figure 141: Antrim Value Proportion Analysis, 2022
Figure 142: Global Vs. Antrim Growth Comparison
Figure 143: Antrim Business Share Analysis (%) by Product, 2022 & 2033
Figure 144: Antrim Business Share Analysis (%) by Indication, 2022 & 2033
Figure 145: Antrim Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 146: Armagh Value Proportion Analysis, 2022
Figure 147: Global Vs. Armagh Growth Comparison
Figure 148: Armagh Business Share Analysis (%) by Product, 2022 & 2033
Figure 149: Armagh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 150: Armagh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 151: Down Value Proportion Analysis, 2022
Figure 152: Global Vs. Down Growth Comparison
Figure 153: Down Business Share Analysis (%) by Product, 2022 & 2033
Figure 154: Down Business Share Analysis (%) by Indication, 2022 & 2033
Figure 155: Down Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 156: Fermanagh Value Proportion Analysis, 2022
Figure 157: Global Vs. Fermanagh Growth Comparison
Figure 158: Fermanagh Business Share Analysis (%) by Product, 2022 & 2033
Figure 159: Fermanagh Business Share Analysis (%) by Indication, 2022 & 2033
Figure 160: Fermanagh Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Figure 161: Rest of Northern Ireland Value Proportion Analysis, 2022
Figure 162: Global Vs. Rest of Northern Ireland Growth Comparison
Figure 163: Rest of Northern Ireland Business Share Analysis (%) by Product, 2022 & 2033
Figure 164: Rest of Northern Ireland Business Share Analysis (%) by Indication, 2022 & 2033
Figure 165: Rest of Northern Ireland Business Share Analysis (%) by Distribution Channel, 2022 & 2033
Total revenue is set to reach USD 232.4 million in 2023.
The target business is expected to be valued at USD 293.3 million by 2033.
The drug segment is expected to witness a high CAGR of 5.2% through 2033.
Demand in the United Kingdom is set to rise at a 2.4% CAGR through 2033.
The target business exhibited a 1.2% CAGR from 2018 to 2022.
England will likely hold about 75.7% value share in the United Kingdom in 2033.
Dysphagia affects around 4 million people in the United Kingdom.
Speech-language pathologists, otolaryngologists, gastroenterologists, and neurologists.
Speech and language therapist, physiotherapist, occupational therapist, dietician, and nursing staff.
Explore Similar Insights
Dysphagia Management Industry Analysis in the United Kingdom
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
